Moreover, the DETECT III study compared standard therapy alone or in combination with anti-HER2 targeted therapy (lapatinib) in patients with HER2-negative metastatic BC and HER2-positive CTCs [53]. The gene discussed is ERBB2; the disease is breast cancer.